Associate Professor, Medicine, University of Washington School of Medicine
Oncology
Dr. Ajay K. Gopal, MD
|
|
Give Review
Ajay Gopal works in the field of Oncology. He has 1 awards "Regional Top Doctor". Ajay K. Gopal is also published. He has 90 publications published. The lastest publication: "Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Pretransplant minimal residual disease predicts survival in mantle Cell lymphoma patients undergoing autologous stem Cell transplantation in complete remission.
- Anti-CD45 radioimmunotherapy without TBI before BMT facilitates persistent haploidentical donor enGraftment in a murine model.
- A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or...
- Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(™) therapeutic protein, for relapsed or refractory NHL patients.
- Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin Lymphoma.
- Treatment of relapsed classical Hodgkin Lymphoma in the brentuximab vedotin era.
- 90Y-ibritumomab tiuxetan therapy in allogeneic transplantation in B-cell lymphoma with extensive marrow involvement and chronic lymphocytic Leukemia: utility of pretra...
- Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation.
- Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.
- Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin Lymphoma patients can increase the proportion achieving FDG PET negative status.
- Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent l...
- Autologous transplant for relapsed follicular Lymphoma: impact of pre-transplant rituximab sensitivity.
- Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelody...
- Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age ≥ 60 Years with B Cell Lymphoma.
- A Preclinical Model of CD38-Pretargeted Radioimmunotherapy for Plasma Cell Malignancies.
- Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive Lymphomas: a retrospective evaluation of safety and efficacy.
- PI3Kdelta Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.
- A Phase 1 Study Evaluating the Safety and Tolerability of Otlertuzumab (TRU-016), an Anti-CD37 Mono-specific ADAPTIRTM Therapeutic Protein in Chronic Lymphocytic Leuke...
- A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP-Rituximab versus CHOP + 131Iodine--Tositumomab.
- CYP3A-Mediated Drug-Drug Interaction Potential and Excretion of Brentuximab Vedotin, an Antibody-Drug Conjugate, in Patients With CD30-Positive Hematologic Malignancies.
- Specific Features Identify Patients with Relapsed or Refractory Mantle Cell Lymphoma Benefitting from Autologous Hematopoietic Cell Transplantation.
- Anti-CD45 radioimmunotherapy using 211At with bone marrow transplantation prolongs survival in a disseminated murine Leukemia model.
- Phase III Randomized Intergroup Trial of CHOP Plus Rituximab Compared With CHOP Chemotherapy Plus 131Iodine-Tositumomab for Previously Untreated Follicular Non-Hodgkin...
- A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed Lymphoma.
- 131I-tositumomab myeloablative radioimmunotherapy for non-Hodgkin's Lymphoma: radiation dose to the testes.
- Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem Cell transplantation.
- Allogeneic hematopoietic Cell transplantation in mantle Cell lymphoma.
- Allogeneic hematopoietic Cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy.
- Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neo...
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma.
- Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem Cell transplantation.
- Pretargeted Radioimmunotherapy using Genetically Engineered Antibody-Streptavidin Fusion Proteins for Treatment of Non-Hodgkin Lymphoma.
- In-vivo purging of the circulating clonal T-Cells with Alemtuzumab prior to autologous peripheral blood hematopoietic Cell mobilization and transplantation.
- Mantle Cell Lymphoma International Prognostic Index but Not Pretransplantation Induction Regimen Predicts Survival for Patients With Mantle-Cell Lymphoma Receiving Hig...
- Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid Leukemia xenograft model.
- 90Y-ibritumomab tiuxetan, fludarabine, and TBI based non-myeloablative allogeneic transplant conditioning for patients with persistent high-risk B-Cell lymphoma.
- Histology and Time to Progression Predict Survival for Lymphoma Recurring after Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation.
- Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic Cell transplantation fo...
- Blood-based detection of radiation exposure in humans based on novel phospho-Smc1 ELISA.
- Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin Lymphomas expressing CD20: a preclinical model toward optimal consoli...
- Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory Lymphoma: a prospective multi-center phase II study ...
- Recent advances in novel radioimmunotherapeutic approaches for allogeneic hematopoietic Cell transplantation.
- Relapsed mantle Cell lymphoma presenting as "sister Mary joseph nodule".
- Allogeneic hematopoietic Cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients...
- Pretargeting CD45 enhances the selective deLivery of radiation to hematolymphoid tissues in nonhuman primates.
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large Cell lymphoma.
- 131I anti-CD45 radioimmunotherapy effectively targets and treats T-Cell non-Hodgkin lymphoma.
- A comparative analysis of conventional and pretargeted radioimmunotherapy of B-Cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations.
- Successful use of full-dose dexamethasone, high-dose cytarabine, and cisplatin as part of initial therapy in non-hodgkin and hodgkin Lymphoma with severe hepatic dysfu...
- Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid Leukemia.
- Radioimmunoconjugates in hematopoietic stem Cell transplantation.
- High-dose chemotherapy with BEAM or Busulphan/Melphalan and Thiotepa followed by hematopoietic Cell transplantation in malignant lymphoma.
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle Cell lymphoma using genetically modified autologous CD20-specific T Cells.
- High-dose therapy and autologous stem Cell transplantation for chemoresistant Hodgkin lymphoma: the Seattle experience.
- Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
- Effect of remission status and induction chemotherapy regimen on outcome of autologous stem Cell transplantation for mantle Cell lymphoma.
- Myeloablative 131I-tositumomab radioimmunotherapy in treating non-Hodgkin's Lymphoma: comparison of dosimetry based on whole-body retention and dose to critical organ ...
- Radioimmunotherapy-based conditioning regimens for stem Cell transplantation.
- Extracorporeal adsorption therapy: a method to improve targeted radiation deLivered by radiometal-labeled monoclonal antibodies.
- Eradication of disseminated Leukemia in a syngeneic murine Leukemia model using pretargeted anti-CD45 radioimmunotherapy.
- Therapeutic use of Rituximab for sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman Disease).
- The impact of histologic grade on the outcome of high-dose therapy and autologous stem Cell transplantation for follicular lymphoma.
- The pretransplant Follicular Lymphoma International Prognostic Index is associated with survival of follicular Lymphoma patients undergoing autologous hematopoietic st...
- Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-Cell lymphomas.
- Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-Cell lymphomas.
- Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid Leukemia cell lines.
- High-dose 131Itositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-Cell transplantation for adults > or = 60 years old with relapsed or refr...
- Improving the efficacy of reduced intensity allogeneic transplantation for Lymphoma using radioimmunotherapy.
- 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of Acute myeloid leukemia in first remiss...
- Glycoprotein IIb/IIIa receptor antagonists: are we ignoring the evidence.
- Ablative allogeneic hematopoietic Cell transplantation in adults 60 years of age and older.
- High-dose (131)I-tositumomab (anti-CD20) radioimmunotherapy for non-Hodgkin's Lymphoma: adjusting radiation absorbed dose to actual organ volumes.
- Fenretinide enhances rituximab-induced cytotoxicity against B-Cell lymphoma xenografts through a caspase-dependent mechanism.
- High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem Cell transplantation for relapsed follicular non-Hodgkin lymphoma:...
- High-dose chemo-radioimmunotherapy with autologous stem Cell support for relapsed mantle Cell lymphoma.
- Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B Cells.
- Efficacy of high-dose therapy and autologous hematopoietic stem Cell transplantation for non-Hodgkin''s lymphoma in adults 60 years of age and older.
- A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem Cell transplantation for relapsed B-Cell lymphomas.
- Prospective analysis of Staphylococcus aureus bacteremia in nonneutropenic adults with malignancy.
- Staphylococcus aureus bacteremia in the surgical patient: a prospective analysis of 73 postoperative patients who developed Staphylococcus aureus bacteremia at a terti...
- Cranial computed tomography before lumbar puncture: a prospective clinical evaluation.
- Clinical applications of anti-CD20 antibodies.
- Large cell non-Hodgkin's lymphoma and Hodgkin's disease arising synchronously in a patient with chronic lymphocytic Leukemia: importance of immunocytochemistry.
- Fatal outcome due to cyclosporine neurotoxicity with associated pathological findings.
- Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious Diseases specialists: experience with 244 patients.
- Role of echocardiography in evaluation of patients with Staphylococcus aureus bacteremia: experience in 103 patients.
- Clinical utility of blood cultures in adult patients with community-acquired pneumonia without defined underlying risks.
- Comparative Efficacy of 177Lu and 90Y for Anti-CD20 Pretargeted Radioimmunotherapy in Murine Lymphoma Xenograft Models.
- Anti-CD45 Radioimmunotherapy with 90Y but Not 177Lu Is Effective Treatment in a Syngeneic Murine Leukemia Model.
Schools
Emory University
Duke University Med Center
University Of Wa School Of Med
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Regional Top Doctor
Education
-
University of Washington -
Duke University Hospital
Drug Facts
| NPI NUMBER | 1194801902 | |
| NPPES Provider LastName | GOPAL | |
| NPPES Provider FirstName | AJAY | |
| NPPES Provider ZIPCode | 98109 | |
| NPPES Provider State | WA | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 93.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1194801902 |
| Last Name Of The Provider | GOPAL |
| First Name Of The Provider | AJAY |
| View All |
Similar Doctors
|
|
Dr. Mary L. Disis, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael S. Milder, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Elihu H. Estey, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Frederick R. Appelbaum, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Heather H. Cheng, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Diana F. Hausman, MD |
|
|
Dr. Maxwell M. Krem, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sam H. Whiting, MD |